ba2blcksheep
2021-10-29
tku pls like me
Gilead trims 2021 sales forecast for non-COVID products
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":857067419,"tweetId":"857067419","gmtCreate":1635496233937,"gmtModify":1635496234083,"author":{"id":4091367214252370,"idStr":"4091367214252370","authorId":4091367214252370,"authorIdStr":"4091367214252370","name":"ba2blcksheep","avatar":"https://static.tigerbbs.com/0f415c93d67440eac8b616c14a4e6b2b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>tku pls like me</p></body></html>","htmlText":"<html><head></head><body><p>tku pls like me</p></body></html>","text":"tku pls like me","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/857067419","repostId":1147570640,"repostType":4,"repost":{"id":"1147570640","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1635463369,"share":"https://www.laohu8.com/m/news/1147570640?lang=&edition=full","pubTime":"2021-10-29 07:22","market":"us","language":"en","title":"Gilead trims 2021 sales forecast for non-COVID products","url":"https://stock-news.laohu8.com/highlight/detail?id=1147570640","media":"Reuters","summary":"Oct 28 (Reuters) - Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earning","content":"<p>Oct 28 (Reuters) - Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.</p>\n<p>Without Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.</p>\n<p>Gilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.</p>\n<p>The biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.</p>\n<p>\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.</p>\n<p>The company's shares, which closed at $67.34, were down 2% at $66 in extended trading.</p>\n<p><img src=\"https://static.tigerbbs.com/bb57f1c1d44cce1af6c37e25db1f4a49\" tg-width=\"847\" tg-height=\"621\" width=\"100%\" height=\"auto\"></p>\n<p>Gilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.</p>\n<p>Revenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.</p>\n<p>But the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.</p>\n<p>Gilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.</p>\n<p>Use of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.</p>\n<p>Third-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.</p>\n<p>Sales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.</p>\n<p>Gilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.</p>\n<p>Including Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead trims 2021 sales forecast for non-COVID products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead trims 2021 sales forecast for non-COVID products\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-29 07:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Oct 28 (Reuters) - Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.</p>\n<p>Without Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.</p>\n<p>Gilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.</p>\n<p>The biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.</p>\n<p>\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.</p>\n<p>The company's shares, which closed at $67.34, were down 2% at $66 in extended trading.</p>\n<p><img src=\"https://static.tigerbbs.com/bb57f1c1d44cce1af6c37e25db1f4a49\" tg-width=\"847\" tg-height=\"621\" width=\"100%\" height=\"auto\"></p>\n<p>Gilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.</p>\n<p>Revenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.</p>\n<p>But the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.</p>\n<p>Gilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.</p>\n<p>Use of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.</p>\n<p>Third-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.</p>\n<p>Sales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.</p>\n<p>Gilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.</p>\n<p>Including Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147570640","content_text":"Oct 28 (Reuters) - Gilead Sciences Inc on Thursday posted higher-than-expected third-quarter earnings on strong demand for its COVID-19 antiviral treatment, but said 2021 sales of its other drugs will fall short of earlier estimates.\nWithout Veklury, also known as remdesivir, Gilead said it now expects sales for the full year of around $21.5 billion. That is down from its previous mid-point estimate of $21.8 billion, reflecting the longer than expected impact of the pandemic on its business.\nGilead has said that sales, particularly of its flagship HIV drugs, have been hurt during the pandemic as many people avoided healthcare settings.\nThe biotechnology company also said results from a key trial of its drug Trodelvy in patients with a specific type of breast cancer have been delayed from this year until at least late January. The medication was the main driver of Gilead's $21 billion purchase of Immunomedics last year.\n\"Nothing has changed in regard to our confidence\", Chief Executive Daniel O'Day said about the trial, on a conference call.\nThe company's shares, which closed at $67.34, were down 2% at $66 in extended trading.\n\nGilead reported adjusted quarterly earnings of $2.65 per share, soundly beating Wall Street estimates of $1.75 per share, as compiled by Refinitiv.\nRevenue for the quarter rose 13% from a year earlier to $7.4 billion, ahead of the average analyst estimate of $6.26 billion.\nBut the outperformance was almost entirely driven by sales of Veklury, which more than doubled to $1.9 billion for the quarter.\nGilead's results were described as \"mixed\" by Jefferies analyst Michael Yee. Aside from Veklury, \"key product line items were generally flattish to lower,\" he said in a research note.\nUse of Veklury, given intravenously to people hospitalized with COVID-19, is driven by pandemic hospitalization rates, which peaked in August and have been falling ever since, Gilead Chief Commercial Officer Johanna Mercier said.\nThird-quarter sales of Gilead's HIV medicines dropped 8% to $4.2 billion as some drugs lost a patent protection and the pandemic continued to limit visits to doctors.\nSales of Trodelvy came in at $101 million for the quarter, in line with analyst estimates.\nGilead raised its full-year adjusted earnings forecast to $7.90 to $8.10 per share from its prior projection of $6.90 to $7.25.\nIncluding Veklury, the company said it now expects product sales for the year of $26 billion to $26.3 billion, up from a previous estimate of $24.4 billion to $25 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":391,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":12,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/857067419"}
精彩评论